Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients

Bookmark and Share
Published: 18 Jun 2019
Views: 361
Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak

Dr Robert Dreicer (UVA Cancer Center, Charlottesville, USA), Dr Richard Schilsky (Chief Medical Officer, ASCO, USA) and Prof Daniel Petrylak (Yale Cancer Center, New Haven, USA) comment on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from a study looking at the use of the novel targeted treatment enfortumab vedotin in urotherial cancer.

The study enrolled urothelial patients who had been treated with platinum-based chemotherapy and/or checkpoint inhibitors.